SCHEMBL20465809

SCHEMBL20465809

COCc1cc(C)cnc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
NOS3 P29474 3/20 0.52
NOS2 P35228 3/20 0.52
NOS1 P29475 2/20 0.52
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
CYP2A6 P11509 2/20 0.38
DHFR P00374 1/20 0.34
ATR Q13535 1/20 0.34
MEN1 O00255 1/20 0.33
PRKCG P05129 1/20 0.33
MAPT P10636 1/20 0.33
PRKCA P17252 1/20 0.33
APEX1 P27695 1/20 0.33
RECQL P46063 1/20 0.33
PRKCE Q02156 1/20 0.33
KMT2A Q03164 1/20 0.33
MYLK Q15746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14832023 0.84 LMNA (0.50) LMNANOS3NOS2NOS1KDM4E
SCHEMBL23534279 0.81 LMNA (0.47) LMNANOS3NOS2NOS1KDM4E
SCHEMBL17490835 0.81 KMT2A (0.48) LMNANOS3NOS2NOS1KDM4E
SCHEMBL2123145 0.81 LMNA (0.47) LMNANOS3NOS2NOS1KDM4E
SCHEMBL31587245 0.79 NOS3 (0.56) LMNANOS3NOS2NOS1CYP2A6
SCHEMBL13283349 0.79 NOS3 (0.56) LMNANOS3NOS2NOS1KDM4E
SCHEMBL12647715 0.79 NOS3 (0.56) LMNANOS3NOS2NOS1CYP2A6
SCHEMBL20465810 0.78 NOS3 (0.54) LMNANOS3NOS2NOS1KDM4E
SCHEMBL17480023 0.78 NOS3 (0.54) LMNANOS3NOS2NOS1KDM4E
SCHEMBL30060571 0.76 LMNA (0.42) LMNANOS3NOS2NOS1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076460-B1 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-12441730-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2025-10-14 US disclosed
US-20230114091-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-13 US disclosed
EP-4076460-A1 PRMT5 INHIBITORS Merck Sharp & Dohme LLC (US) 2022-10-26 EP disclosed
WO-2021126729-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
WO-2021126729-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
US-20180222908-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-09 US disclosed
US-20180222908-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230114091-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 LMNA 1841/4885NOS3 958/4885NOS2 796/4885
US-12441730-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 LMNA 1841/4885NOS3 958/4885NOS2 796/4885
US-20180222908-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS GRM2, GRM5, GRM1 LMNA 4437/4885NOS3 3395/4885NOS2 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.